Pharmaceutical Industry

Drugs

  • Chemical substances used in the treatment, prevention, or diagnosis of diseases.

Biologics

  • vaccines, proteins, antibodies

  • high nuclear weight >2000

  • manufactured using living organisms = plants, animals, cells


Small Molecules

  • low molecular weight <2000

  • manufactured through chemical synthesis or naturally via living orgs.


The Pharmaceutical Industry

  • FDA, Health Canada

  • Research Intensive + high risk + potentially high profit

“Ethical” Innovator (Research-based) Pharmaceutical Companies

  • invest heavily into research

  • discover and develop new molecular entities

ex: Pfizer, AstraZeneca, Johnson & Johnson

Generic Pharmaceutical Companies

  • do not discover new molecular entities

  • enter market through patent expiry/ challenges

  • specialize in manufacturing efficiency + drug formulations

ex: Novartis, Pfizer



Biotech Companies

  • exploit academic discoveries

  • Invest heavily in research

  • Focus on specialized products

ex: Moderna, BioNTech

Contract Research Organizations (CROs)

provide specialized services for the pharmaceutical industry:

  • Biological testing

  • Specialty chemical synthesis

  • Specialty manufacturing

  • Conduct clinical trials

Focus on specific research areas - niche expertise

ex: Paraza Pharma, Altasciences




Molecular Entity vs. Product

molecular entity

  • pure active ingredient

(e.g., Acetaminophen)


product

  • formulation that contains the molecular entity

(e.g. Tylenol)



Typical Drug Project Progression

  1. Idea / Target Identification

  • Identify a drug target (enzyme, receptor, biological pathway)

  • Define a new drug strategy

  • Project initiation & feasibility: Can we do it? Should we do it?


  1. Discovery

  • Identify a lead compound

  • Optimize the lead (potency, selectivity, stability)

  • Result: New Molecular Entity (NME)


  1. Preclinical Development (Trials)

  • In vitro (lab) and in vivo (animal) studies

  • Assess safety, toxicity, dosing, pharmacokinetics (PK)

  • Develop drug formulation (e.g., pill, injection)


  1. Clinical Development (Trials)

  • Phase I: Safety and dosage

  • Phase II: Efficacy and side effects

  • Phase III: Effectiveness in large populations

  • Confirm risk vs. benefit


  1. Market & Post Market

  • Regulatory approval (FDA / Health Canada)

  • Post-marketing surveillance (long-term safety)

  • Identify new indications or uses



New Molecular Entity

  • (NME) -